Biomm S.A (BIOM3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomm S.A (BIOM3) has a cash flow conversion efficiency ratio of -0.164x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$-46.72 Million ≈ $-9.17 Million USD) by net assets (R$284.10 Million ≈ $55.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Biomm S.A (BIOM3) market capitalisation for the company's overall valuation and market capitalisation.
Biomm S.A - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Biomm S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biomm S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomm S.A ranked by their cash flow conversion efficiency. Explore BIOM3 operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gia Lai Electricity JSC
VN:GEG
|
0.076x |
|
Sajodaerim
KO:003960
|
0.051x |
|
Patagonia Gold Corp
V:PGDC
|
-0.104x |
|
Beta Systems Software AG
F:SPT6
|
N/A |
|
MKH Oil Palm (East Kalimantan) Berhad
KLSE:5319
|
0.058x |
|
Aftermath Silver Ltd
V:AAG
|
-0.084x |
|
Cosmax
KO:044820
|
0.073x |
|
Bergbahnen Engelberg Truebsee Titlis Bet AG
SW:TIBN
|
0.055x |
Annual Cash Flow Conversion Efficiency for Biomm S.A (2006–2024)
The table below shows the annual cash flow conversion efficiency of Biomm S.A from 2006 to 2024. View current stock price of Biomm S.A for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | R$262.78 Million ≈ $51.56 Million |
R$-91.84 Million ≈ $-18.02 Million |
-0.350x | +42.54% |
| 2023-12-31 | R$122.94 Million ≈ $24.12 Million |
R$-74.78 Million ≈ $-14.67 Million |
-0.608x | -53.63% |
| 2022-12-31 | R$159.11 Million ≈ $31.22 Million |
R$-63.00 Million ≈ $-12.36 Million |
-0.396x | +52.89% |
| 2021-12-31 | R$111.59 Million ≈ $21.90 Million |
R$-93.78 Million ≈ $-18.40 Million |
-0.840x | -66.12% |
| 2020-12-31 | R$191.48 Million ≈ $37.57 Million |
R$-96.87 Million ≈ $-19.01 Million |
-0.506x | -0.11% |
| 2019-12-31 | R$153.56 Million ≈ $30.13 Million |
R$-77.61 Million ≈ $-15.23 Million |
-0.505x | -21.54% |
| 2018-12-31 | R$106.09 Million ≈ $20.82 Million |
R$-44.12 Million ≈ $-8.66 Million |
-0.416x | +54.67% |
| 2017-12-31 | R$59.30 Million ≈ $11.64 Million |
R$-54.41 Million ≈ $-10.68 Million |
-0.917x | -58.00% |
| 2016-12-31 | R$65.93 Million ≈ $12.94 Million |
R$-38.28 Million ≈ $-7.51 Million |
-0.581x | -380.95% |
| 2015-12-31 | R$115.13 Million ≈ $22.59 Million |
R$-13.90 Million ≈ $-2.73 Million |
-0.121x | +34.64% |
| 2014-12-31 | R$107.10 Million ≈ $21.02 Million |
R$-19.78 Million ≈ $-3.88 Million |
-0.185x | -91.50% |
| 2013-12-31 | R$108.94 Million ≈ $21.38 Million |
R$-10.51 Million ≈ $-2.06 Million |
-0.096x | -129.36% |
| 2012-12-31 | R$-22.00 Million ≈ $-4.32 Million |
R$-7.23 Million ≈ $-1.42 Million |
0.329x | +61.48% |
| 2011-12-31 | R$-8.76 Million ≈ $-1.72 Million |
R$-1.78 Million ≈ $-349.66K |
0.203x | -82.19% |
| 2010-12-31 | R$-4.06 Million ≈ $-796.84K |
R$-4.64 Million ≈ $-910.45K |
1.143x | -99.77% |
| 2009-12-31 | R$-15.00K ≈ $-2.94K |
R$-7.50 Million ≈ $-1.47 Million |
499.733x | +106719.64% |
| 2008-12-31 | R$-12.22 Million ≈ $-2.40 Million |
R$-5.71 Million ≈ $-1.12 Million |
0.468x | -30.15% |
| 2006-12-31 | R$3.09 Million ≈ $606.12K |
R$2.07 Million ≈ $405.98K |
0.670x | -- |
About Biomm S.A
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more